Seer Unveils Latest Data at the 2025 HUPO World Congress
Seer's Announcement: Seer revealed new data to be presented at the HUPO World Congress 2025, highlighting advancements in deep, scalable proteomics and its impact on human disease research.
Research Applications: The Proteograph Product Suite is facilitating research in various fields, including cardiovascular health, oncology, and aging biology, through collaborative and independent studies.
Technological Impact: Seer's technology is enabling scientists to convert complex biological signatures into actionable insights, enhancing the role of proteomics in translational and population-scale research.
Global Collaboration: The findings emphasize the importance of collaborative efforts in advancing scientific understanding and application of proteomics in addressing human health challenges.
Get Free Real-Time Notifications for Any Stock
Analyst Views on SEER
About SEER
About the author

Seer Publishes Large GWAS Study Validating Mass Spectrometry's Role in Proteomics
- Significant Findings: Seer's Proteograph platform detected 5,753 proteins and quantified 1,980 in a GWAS involving approximately 1,600 blood samples, showcasing its robust capabilities in protein research and advancing precision medicine.
- Importance of Validation: The study reveals that about one-third of protein-gene associations reported without mass spectrometry validation do not replicate, underscoring the critical role of mass spectrometry in ensuring the reliability of drug targets and clinical biomarkers, thereby reducing technical noise in research.
- New Discoveries: Among 364 genetic variants associated with protein abundance, 102 were validated in an independent cohort, with 35 being newly reported, thus expanding the knowledge base of genetic regulation of proteins and deepening biomedical research.
- Clinical Impact: By providing more reliable protein measurements, Seer's research lays the groundwork for drug discovery and biomarker development, ensuring that future therapies are built on real biology, which increases the likelihood of success in clinical applications.

Seer Publishes Large GWAS Validating Mass Spectrometry's Role in Proteomics
- Significant Research Findings: Seer's Proteograph platform detected 5,753 proteins and quantified 1,980 in a genome-wide association study involving approximately 1,600 blood samples, showcasing its robust capabilities in protein abundance research and reinforcing the company's leadership in precision medicine.
- Importance of Validation: The study revealed that about one-third of protein-gene associations reported without mass spectrometry validation do not replicate, underscoring the critical role of mass spectrometry in ensuring the reliability of drug targets and clinical biomarkers, thereby enhancing Seer's market competitiveness.
- New Discovery Potential: Among 364 protein quantitative trait loci (pQTLs), 102 were validated in an independent cohort, with 35 being newly reported, which not only expands the knowledge base of protein genetic regulation but also provides new directions for future drug development.
- Clinical Application Prospects: By offering more reliable protein measurements, Seer's research lays the groundwork for drug discovery and biomarker development, reducing risks associated with technical noise and increasing the likelihood of success in clinical research, thus advancing translational medicine.









